Study of mucormycosis patients attending tertiary care hospital: a retrospective study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20191648Keywords:
Amphotericin, Clinical outcome, Diabetes, Mortality, MucormycosisAbstract
Background: Treatment of mucormycosis involves a combination of surgical debridement of involved tissues and antifungal therapy. Intravenous amphotericin B is the drug of choice. In this study authors assessed the outcomes of treating patients with mucormycosis with varied formulations of amphotericin.
Methods: Authors performed a retrospective observational study of patients diagnosed with mucormycosis and admitted in the inpatient ward of Bharati Hospital, Sangli, Maharashtra, India from May 2015 till May 2018. Patients either received amphotericin B, lyophilized amphotericin B or lipid soluble amphotericin B. Resolution of symptoms was graded as good clinical response and persistence of symptoms as poor clinical response.
Results: During the study period a total of 16 patients were included in the study. All patients underwent surgical debridement and received different forms of amphotericin. Three patients received amphotericin B 1.5 to 3 grams over 21 days and responded satisfactory and later had renal toxicity. Five patients received lyophilized amphotericin B 3 to 4 grams over 21 days, with good response and less renal toxicity as compared to amphotericin B. Lipid soluble amphotericin B was given to 8 patients 3.5 to 5 gm over 21 days with good clinical response and minimal renal toxicity. Of the 10 patients who presented with nasal discharge, 60% had a good clinical outcome, 30% had poor and one patient died.
Conclusions: Amphotericin B is an effective anti-fungal. Further studies are needed to assess the utility of immunologic and metabolomic profiling of the host and prescribing targeted immunotherapy in decreasing the incidence of mucormycosis.
References
Kauffman CA, Malani AN. Zygomycosis: an emerging fungal infection with new options for management. Current Infect Dis Reports. 2007;9(6):435-40.
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clinic Infect Dis. 2012;54(1):S16-22.
Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis. Clin Microbiol Infect. 2014;20:5-26.
Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clinic Infect Dis. 2012;54(1):S55-60.
Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clinic Infect Dis. 2008;47(4):503-9.
Diwakar A, Dewan RK, Chowdhary A, Randhawa HS, Khanna G, Gaur SN. Zygomycosis-a case report and overview of the disease in India. Mycoses. 2007;50(4):247-54.
Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta KL, et al. Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect. 2001;42(4):261-6.
Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350-60.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. New Eng J Med. 2007;356(4):348-59.
Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clinic Infect Dis. 2012;54(11):1-8.
Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrobial Agents Chemotherapy. 2010;54(3):1298-304.
Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematol. 2017;102(3):433-44.
Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, et al. French mycosis study group. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrobial Chemotherapy. 2015;70(11):3116-23.
Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases?. Leukaemia Lymphoma. 2004;45(7):1351-60.
Kanafani ZA, Klepser ME. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Invasive Fungal Infect. 2010;4(2).
Ibrahim AS, Gebremariam T, Husseiny MI, Stevens DA, Fu Y, Edwards JE, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrobial Agents Chemotherapy. 2008;52(4):1573-6.
